Existing investor Center Laboratories Group contributed to Tot's series B round, which will fund development of its oncology treatments.
Tot Biopharm, a China-based oncology therapy developer, closed a $102m series B round today that featured biopharmaceutical company Center Laboratories Group.
The round also included financial services provider Yuanta Financial Holdings, healthcare investment firm Vivo Capital, venture capital firm Chengwei Capital, private equity firm Cathay Capital and a vehicle called China Universal (Cayman) GP.
Founded in 2010, Tot Biopharm is creating antibody-drug conjugates, a type of cancer treatment that targets and kills only tumour cells while leaving healthy tissue intact,…
